Sarcopenia in Axial and Peripheral Spondyloarthropathies

NCT ID: NCT03319264

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

106 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-02

Study Completion Date

2018-07-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Spondylarthropathies (SpA) are among the most common chronic inflammatory rheumatisms in adults, responsible for a muscular loss or sarcopenia which can be very disabling, not much documented in the literature, and not yet studied in France. In addition, sarcopenia is associated with decreased physical activity and increased risk of falls and fractures. A better characterization of the determinants of this muscular loss will allow to better detect and take care of it.

The aim is to conduct the first French study on the prevalence and severity of sarcopenia in patients with spondyloarthropathies and to study the variables that may be associated with it. Finally, we propose to evaluate obesity related to sarcopenia in these patients and compare them to cases matched for age and sex (from OFELY / STRAMBO cohorts, Lyon, FRANCE).

This is a prospective interventional and monocentric study with minimal risks and constraints: patients will be included for one day for an evaluation of their sarcopenia by measuring their muscle strength, physical performance and body composition and recording of their socio-demographic and disease characteristics.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spondylarthropathy Sarcopenia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Spondylarthropathy Sarcopenia lean mass fat mass

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with SpA

Patients included in this single group study will have 3 interventions to assess the severity of muscle loss :

* dynamometry exam
* walking test
* Dual-energy X-ray Absorptiometry (DXA) measurement Quality of life will be assessed with Sarcopenia \& Quality of Life (SARQOL) questionnaire. Patients will also fill a Life habits Questionnaire.

Group Type EXPERIMENTAL

Dynamometry exam

Intervention Type OTHER

Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength

Walking test

Intervention Type OTHER

A 4 metres walking test will be performed to assess patient's walking speed

DXA measurement

Intervention Type RADIATION

DXA measurement will be performed to assess patient's body composition

SARQOL questionnaire

Intervention Type OTHER

Patient's quality of life will be assessed thanks to the SARQOL questionnaire

Life habits Questionnaire

Intervention Type BEHAVIORAL

Life habits Questionnaire

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dynamometry exam

Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength

Intervention Type OTHER

Walking test

A 4 metres walking test will be performed to assess patient's walking speed

Intervention Type OTHER

DXA measurement

DXA measurement will be performed to assess patient's body composition

Intervention Type RADIATION

SARQOL questionnaire

Patient's quality of life will be assessed thanks to the SARQOL questionnaire

Intervention Type OTHER

Life habits Questionnaire

Life habits Questionnaire

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women, 18 to 80 years old
* Hospitalized or attending the rheumatology department for spondyloarthopathy.

Exclusion Criteria

* no signed consent
* Immobilization for a period of more than 15 days during the last 3 months
* pregnant or breastfeeding woman
* Not affiliated to the national healthcare insurance
* difficulty in understanding French
* psychiatric disorder
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Rhumatologie - Hôpital Edouard Herriot

Lyon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Merle B, Cottard M, Sornay-Rendu E, Szulc P, Chapurlat R. Spondyloarthritis and Sarcopenia: Prevalence of Probable Sarcopenia and its Impact on Disease Burden: The Saspar Study. Calcif Tissue Int. 2023 Jun;112(6):647-655. doi: 10.1007/s00223-023-01074-3. Epub 2023 Mar 21.

Reference Type RESULT
PMID: 36944706 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-A02391-52

Identifier Type: OTHER

Identifier Source: secondary_id

69HCL17_0145

Identifier Type: -

Identifier Source: org_study_id